Tips For Partnering With Health Systems: A Critical Step For CGT Commercialization

Transitioning Cell and Gene Therapy (CGT) from clinical trials to commercial availability involves significant operational and financial shifts for health systems. Processes that worked in a research setting are rarely scalable for routine, day-to-day patient care. Early and in-depth collaboration between CGT manufacturers and health systems is crucial for overcoming these hurdles and maximizing patient access.

To ensure a smooth transition, manufacturers must work closely with health systems to adapt to commercial realities. This involves recognizing the complexities of the medication-use process—from procurement to administration and monitoring. Health systems need clear answers on logistics, accreditation, patient support, and reimbursement to confidently integrate a new therapy. Manufacturers should also prepare for post-commercialization challenges, such as aligning payment timing to mitigate financial risk and providing clear protocols for when a commercial product fails to meet specifications. By understanding and addressing these pain points proactively, manufacturers can become effective partners and accelerate the integration of these critical therapies.

Read the full article to discover key questions health systems need answered and strategies for more effective collaboration.